Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Posts Strong Q2 Revenue Gains; Income Down on Charge

NEW YORK, July 28 (GenomeWeb News) - Invitrogen today reported a 21 percent increase in second-quarter revenue year over year, but a 24 percent drop in net earnings due to a one-time charge.

The Carlsbad, Calif.-based firm reported revenue of $306.5 million compared with $254 million in the second quarter last year. The company also beat analysts' consensus estimate of $301 million for the quarter.

Invitrogen's organic revenue growth was 7 percent, with 2 percent of growth coming from currency benefits and 12 percent attributed to acquisitions.

During the quarter, the company completed its acquisitions of Dynal Biotech and Caltag Laboratories, two of several purchases the company has made this year. Earlier this week, Invitrogen announced that it would acquire proteins and reagents firm BioSource International for $130 million in cash.

Revenue growth was strongest in Invitrogen's BioDiscovery segment, which had 30 percent sales growth year over year, while the BioProduction unit had revenue growth of 9 percent.

The firm's R&D spending increased to $24.3 million from $18.2 million in the comparable quarter last year.

Invitrogen's net earnings dropped to $14.9 million, or $.27 per share, from $19.7 million, or $.36 per share, in the second quarter last year. However, the firm noted that it took a one-time charge of $13 million in the most recent quarter related to costs associated with its purchase of Dynal.

The company is forecasting fiscal 2005 revenue of $1.2 billion and earnings per share of $3.50 to $3.53.

As of June 30, Invitrogen held $931.9 million in cash and investments.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.